Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%

    Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%

PR Newswire

ALLEGAN, Mich., Feb. 1, 2013

ALLEGAN, Mich., Feb. 1, 2013 /PRNewswire/ --Perrigo Company (Nasdaq:
PRGO;TASE) today announced that it has launched clobetasol emulsion propionate
foam, 0.05%, the generic equivalent of Olux® -E Foam, 0.05%.Perrigo will
commence shipment of the product immediately.As Perrigo was the first generic
filer against this product, it has 180 days of generic exclusivity.The launch
date was agreed upon in a 2012 litigation settlement between Perrigo and

(Logo: )

Clobetasol emulsion propionate foam, 0.05% is indicated for the treatment of
moderate to severe dermatosis of the scalp. Generic annual sales were
approximately $38 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is the
second product launched since the acquisition of Cobrek and it's another
example of our Rx team's commitment to launching difficult to manufacture
products. We are excited to market this product and are dedicated to making
quality healthcare more affordable."

Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes OTC and generic prescription (Rx)
pharmaceuticals, infant formulas, nutritional products, and active
pharmaceutical ingredients (API). The Company is the world's largest
manufacturer of OTC pharmaceutical products and infant formulas, both for the
store brand market. The Company's primary markets and locations of
manufacturing and logistics operations are the United States, Israel, Mexico,
the United Kingdom and Australia. Visit Perrigo on the Internet

Note: Certain statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections. While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 25, 2011, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Perrigo Company

Contact: Arthur J. Shannon, Vice President, Investor Relations and
Communication, +1-269-686-1709,; or Bradley Joseph,
Senior Manager, Investor Relations and Communication, +1-269-686-3373,
Press spacebar to pause and continue. Press esc to stop.